LONDON--(BUSINESS WIRE)--Vertex Pharmaceuticals (Nasdaq: VRTX) today announced that the European Commission has granted approval for the label expansion of KALYDECO® (ivacaftor) for the treatment of infants down to 1 month of age with cystic fibrosis (CF) who have one of the following mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene: R117H, G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N or S549R.
Vertex’s cystic fibrosis triple combo is poised to become the top-selling orphan drug in terms of net present value, amid shifting sentiments in the pharma industry for rare disease drugs, according to Evaluate.
Vertex will pay $25 million upfront for TreeFrog Therapeutics’ cell manufacturing technology that can help boost production of its early-phase type 1 diabetes assets.
Vertex Pharmaceuticals Incorporated, a global biotechnology company investing in scientific innovation to create transformative medicines for people with serious diseases, has announced important advancements across its suzetrigine pain programme, which has the potential to be the first new class of medicine for acute and neuropathic pain in more than two decades. Suzetrigine is an oral selective NaV1.8 pain signal inhibitor (formerly known as VX-548).
Will Vertex’s “pipeline-in-a-product” pay off?That’s the bet behind the company’s $4.9 billion acquisition of Alpine Immune Sciences and its mid-stage IgA nephropathy drug, which is designed to inhibit two key cytokines.
Vertex begins bid for US approval of non-opioid painkiller
Vertex Announces Advancements of Suzetrigine (VX-548) in Acute and Neuropathic Pain
Vertex to Announce First Quarter 2024 Financial Results on May 6
Vertex Pharmaceuticals moved from Cambridge to Boston’s Seaport a decade ago, it signaled that what was then a sea of parking lots could be a booming business district, and galvanized a wave of new development.
Vertex Announces FDA Clearance of Investigational New Drug Application for VX-407 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)